PhD-student
Angela el Hebieshy
Research:
Conjugated antibodies are indispensable tools for research, diagnostics, and therapeutics. They span from fluorescently labelled antibodies for imaging, to bi-specific antibodies for dual targeting, and antibody-drug conjugates (ADRs) for selective delivery of cytotoxic agents. Two major challenges are the heterogeneity of conjugated antibodies, and their immunogenicity when used therapeutically. To address these issues, I am currently developing a novel method for site-directed antibody conjugation using a non-immunogenic small protein tag.
Curriculum Vitae:
I studied Clinical Pharmacy at the Suez Canal University, Egypt and obtained my Masters’ degree in Molecular Pharmacology at the VU University Amsterdam, The Netherlands. In 2014, I joined the Chemical Biology lab of Huib Ovaa at the Netherlands Cancer Institute, where I did my final internship investigating ubiquitin binding domains. After completion of my master studies, I joined the Ovaa group as a technician, and in 2016 I started my PhD focusing on multivalent and bi-specific antibody fragments.
Publications
-
Total Chemical Synthesis of a Functionalized GFP Nanobody
Huppelschoten Y, Elhebieshy AF, Hameed DS, Sapmaz A, Buchardt J, Nielsen TE, Ovaa H, van der Heden van Noort GJ.
Chembiochem. 2022, doi: 10.1002/cbic.202200304, PMID: 35920208
-
Thermal-exchange HLA-E multimers reveal specificity in HLA-E and NKG2A/CD94 complex interactions
Ruibal P, Derksen I, van Wolfswinkel M, Voogd L, Franken KLMC, El Hebieshy AF, van Hall T, Schoufour TAW, Wijdeven RH, Ottenhoff THM, Scheeren FA, Joosten SA.
Immunology. 2023, doi: 10.1111/imm.13591. PMID: 36217755
